Serguei Kozlov,
Leidos Biomedical Research, Inc. Principal Scientist
Principal Scientist/PM, CAPR, Leidos Biomedical Research, Inc.
Internationally recognized expert in advanced methodologies of generating diverse preclinical murine models (including genetically engineered mouse (GEM) models, GEM-derived syngeneic allograft (GDA) models, patient-derived (PDX) and conventional cell lines-based xenograft models) for studies of the molecular mechanisms of carcinogenesis, tumor immune response, immune surveillance, and inflammation, mechanisms of drug resistance, implication of cancer stem cells, etc.; and to explore such models for preclinical drug development, disease systems analyses and biomarker discovery. Initiated, supervised, and successfully conducted multiple research projects and independent large-scale research and development programs aimed at investigation of molecular mechanisms governing carcinogenesis, biomarker discovery and preclinical drug evaluation in GEM vs. GDA vs. PDX mouse models. Oversee from day one launch and operations of the NCI Center for Advanced Preclinical Research – an innovative preclinical cancer modeling and drug development initiative based on genetically engineered murine models – with senior management responsibilities. Co-authored over 60 scientific papers, book chapters and original works in peer-reviewed journals.
|
|
|
